)

New companies

Vivet Therapeutics

Vivet Therapeutics (“Vivet”) is an emerging biotechnology company developing novel gene therapy treatments for rare, inherited metabolic diseases. Vivet is building a diversified gene therapy pipeline based on novel adeno-associated virus (AAV) technologies developed through its partnerships with, and exclusive licenses from, the Fundación para la Investigación Médica Aplicada (FIMA), a not-for-profit foundation managing the Centro de Investigación Médica Aplicada (CIMA, University of Navarra), the biomedical research center of the Clinica Universidad de Navarra,  based in Pamplona, Spain.

Vivet was created in Paris, France, with a wholly-owned subsidiary in Spain, in 2016 by Gloria González  Aseguinolaza (CIMA, University of Navarra), Jean Philippe Combal ex Gensight Biologics, Sanofi) and Jens Kurth (ex Anokion, Novartis),  bringing together significant experience and expertise in gene therapy, liver diseases and global drug discovery and development for rare diseases.

Vivet was originally funded by international life science investors including Novartis Venture Fund, Roche Venture Fund, HealthCap, Columbus Venture Partners, Ysios Capital, Kurma Partners and Idinvest Partners. FIMA also holds a minority equity stake of Vivet.

On March 20, 2019 Vivet and Pfizer Inc. (NYSE: PFE) announced that Pfizer has acquired a 15% equity interest in Vivet and secured an exclusive option to acquire all outstanding shares. Pfizer and Vivet will collaborate on the development of VTX-801, Vivet’s proprietary treatment for Wilson disease.

According to Dr. González Aseguinolaza, CSO of Vivet “The potential of VTX-801 has already been demonstrated in preclinical models and our partnership with Pfizer will help accelerate development of VTX-801 and expand our other innovative technologies.” Jean-Phillippe Combal, CEO of Vivet, said, “We welcome Pfizer as a shareholder and partner that can help us advance our efforts to develop therapies for patients burdened with inherited liver disorders. This investment demonstrates the clear value of Vivet’s innovative approaches to gene therapy.”

Read more: https://www.vivet-therapeutics.com

 
Handl Therapeutics

Handl Therapeutics is an emerging biotechnology company specializing in the development of gene therapy to treat neurodegenerative diseases. This company is focused on the development of new proprietary technologies based on the use of adeno-associated viruses (AAV) and their clinical outcome.

It was created on September 30th, 2019 in Leuven (Belgium) with capital from an international investment group. Operating with a highly collaborative approach, the company relies on the integration of knowledge and experience from a strong international network of global biotechnology and research centres. Thus, it combines the cutting-edge scientific and technological advances of the Cima Universidad de Navarra, the University of Louvain (Belgium) and the University of Santiago de Chile (Chile).

Handl Therapeutics has established exclusive collaboration and license agreements with the Fundación para la Investigación Médica Aplicada (FIMA), a not-for-profit foundation managing the biomedical research centre Cima Universidad de Navarra. Those agreements are based on Cima's research results for the treatment of Parkinson's disease. That partnership will allow the development of a vector of gene therapy capable of attenuating and stopping cell death of dopamine-producing brain neurons, a characteristic process of the disease mentioned above.

Under the leadership of Dr José Luis Lanciego, senior researcher in Parkinson's disease and co-promoter of this entrepreneurship initiative, the Cima researchers, together with Handl Therapeutics, are undertaking the preclinical development of this technology to reach the first trials clinical trials in patients affected by this neurodegenerative disease in early 2023.

On November 12th, 2020, the multinational biopharmaceutical company UCB announced the acquisition of Handl Therapeutics. With this commitment, UCB seeks to strengthen its activities in gene therapy for neurological and immunological treatments. UCB is a company focused on the research and development of treatments mainly directed at Parkinson's disease, Alzheimer's, Epilepsy, and Crohn's disease.

Handl Therapeutics: https://www.handltherapeutics.com/

Neurosciences Program: https://cima.unav.edu/en/investigacion/programas-verticales/neurociencias/parkinson

Start-ups y Spin-offs
  • Aligen Therapeutics.
    Company focused on cardiovascular diseases

    Aligen Therapeutics is a spin out of the Center for Applied Medical Research (CIMA), of the University of Navarra, Spain. Aligen holds licenses of CIMA’s patents and know-how on cardiovascular research. The aim of the establishment, fully owned by CIMA, is to be a business-friendly interface with investors, while keeping a privileged access to CIMA’s researchers and facilities.

    TEASER: "New antihemorrhagic agents: a novel antifibrinolytic strategy"

    Update date: September 2018


    Contact:
    Business Development Unit: bdcima@unav.es

  • Epical Biosciences.
    Company focused on cancer research

    Epical Biosciences is a spin out of the Center for Applied Medical Research (CIMA), of the University of Navarra, Spain. Epical Biosciences holds licenses of CIMA’s patents and know-how on cancer research. The aim of the establishment, fully owned by CIMA, is to be a business-friendly interface with investors, while keeping a privileged access to CIMA’s researchers and facilities.

    TEASER: "New epigenetic agents: therapeutic approach in cancer"

    Update date: September 2018


    Contact:
    Business Development Unit: bdcima@unav.es

Business development

Contact:
Centro de Investigación Médica Aplicada (CIMA)
Avenida Pío XII, 55
31008 Pamplona
España

+34 948 194 700
bdcima@unav.es

Notice

The University of Navarra uses cookies to improve its services, generate statistical data and analyze the browsing habits of visitors to its website. This information may be shared with third parties as detailed in the Cookies Policy Statement. By clicking “I agree” or continuing to browse, you consent to the use of these cookies, while reserving the right to reverse the decision at will.

Agree